Skip to content

Krystal Biotech, Inc. KRYS Other operating expenses

Other operating expenses at other companies

TG Therapeutics logo
TG TherapeuticsTGTX
$73.14M+89.0%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$3.96M+303%
Insmed logo
InsmedINSM
-0.1%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$200K
Biogen logo
BiogenBIIB
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s other operating expenses?
Krystal Biotech, Inc. (KRYS) reported other operating expenses of $62.67M in Q1 2026.
How has Krystal Biotech, Inc.'s other operating expenses changed year-over-year?
Krystal Biotech, Inc.'s other operating expenses increased by 20.7% year-over-year, from $51.93M to $62.67M.
What is the long-term trend for Krystal Biotech, Inc.'s other operating expenses?
Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s other operating expenses has grown at a 35.2% compound annual growth rate (CAGR), from $68.27M to $227.93M.